Be Biopharma develops engineered B cell medicines for serious genetic diseases.
Be Biopharma has raised $92.0M in total funding. The most recent round was Series C. The last funding was announced in January 2025.
Be Biopharma's investors include RA Capital Management, ARCH Venture Partners, Longwood Fund, Atlas Venture, Bristol-Myers Squibb.
Be Biopharma is headquartered in Cambridge, United States.
Be Biopharma develops engineered B cell medicines for serious genetic diseases.
Be Biopharma is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Be Biopharma — Funding & Investors." VCBacked, January 15, 2025, https://www.vcbacked.co/company/be-biopharma. Accessed July 20, 2026.
VCBacked. (2025). Be Biopharma — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/be-biopharma
{{cite web |title=Be Biopharma — Funding & Investors |url=https://www.vcbacked.co/company/be-biopharma |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated